Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of semaglutide, describes the unprecedented growth of the obesity market and what might come next for Novo.

Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts. 

Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?

The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.